CD274 and non-small cell lung carcinoma: The United States Food and Drug Administration has approved two PD-1 inhibitors (nivolumab and pembrolizumab) and one programmed cell death-ligand 1 (PD-L1) inhibitor (atezolizumab) for previously treated non-small-cell lung cancer (NSCLC).